IndraLab

Statements

USP29 inhibits TAK1-JNK. 3 / 3
| 3
reach
"USP29 inhibits TAK1-JNK/p38 pathway activation during hepatic I/R injury."
37304282
reach
"Taken together, these results suggest that USP29 inhibits the activation of the TAK1-JNK/p38 pathway during hepatic I/R injury."
37304282
reach
"We found that USP29 knockout significantly promoted TAK1-JNK/p38 pathway activation after the H/R challenge However, this effect was countered by blocking TAK1 activation (Figure 8A)."
37304282